A Single-dose Daclizumab Induction Protocol in Renal Allograft Recipients: A Chinese Single Center Experience

Transplantation Proceedings

Volumn 39, Issue 5, 2007, Pages 1396-1401

  Ji, S M ^a   Li, L S ^b   Cheng, Z ^a   Cheng, D R ^a   Sun, Q Q ^a   Chen, J S ^a   Sha, G Z ^a   Liu, Z H ^b  

^a JINLING HOSPITAL   (China)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; DACLIZUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; ANAPHYLAXIS; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE SYNDROME; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; GRAFT INFECTION; GRAFT SURVIVAL; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOPATHOLOGY; IMMUNOPROPHYLAXIS; KIDNEY ALLOGRAFT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; LEUKOPENIA; LUNG INFECTION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; URINARY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; CHINA; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; SURVIVORS; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 34250189454     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2006.11.016     Document Type: Article

References (18)

1. Samsel R., Rowinski W., Chmura A., et al. Perioperative administration of single, high-dose of ATG-Fresenius-S as an induction immunosuppressive therapy in cadaveric renal transplantation: preliminary results. Transplant Proc 33 (2001) 2952
2. Hibberd A.D., Trevillian J.H., Wlodarzcyk J.H., et al. Cancer risk associated with ATG/OKT3 in renal transplantation. Transplant Proc 31 (1999) 1271
3. Kupeic-Weglinski J.W., Diamantstein T., and Tinley N.L. Interleukin 2 receptor-targeted therapy - rationale and applications in organ transplantation. Transplantation 46 (1988) 785
4. Pascual J., Marcén R., and Ortuǒ J. Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab. Nephrol Dial Transplant 16 (2001) 1756
5. Deierhoi M.H., Hudson S.L., and Gaston R.S. Clinical experience with a two dose regimen of daclizumab in cadaveric renal transplantation. [abstract]. Transplantation 69 (2000) S260
6. Shuming J., Guang Y., Jinsong C., et al. Clinical trial of daclizumab on prevention of acute rejection after kidney transplantation. J Transpl 2 (2004) 65
7. Bumgardner G.L., Hardie I., Johnson R.W.G., et al. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation 72 (2001) 839
8. Racusen L.C., Solez K., Colvin R.B., et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 55 (1999) 713
9. Qiquan S., Zhi-Hong L., Guang Y., et al. Tacrolimus combined with mycophenolate mofetil can effectively reverse C4d-positive steroid-resistant acute rejection in Chinese renal allograft recipients. Nephrol Dial Transplant 21 (2005) 510
10. Sanfilippo F., Vaughn W.K., Spees E.K., et al. The detrimental effects of delayed graft function in cadaver renal transplantation. Transplantation 38 (1984) 643
11. Hetzel G.R., Klein B., Brause M., et al. Risk factors for delayed graft function after renal transplantation and their significance for long-term clinical outcome. Transpl Int 15 (2002) 10
12. Vincenti F., Kirkman R., Light S., et al. Interleukin-2-receptor blockade with daclizumab to provent acute rejection in renal transplantation. N Engl J Med 338 (1998) 161
13. Ekberg H., Persson N.H., Källen R., et al. Two doses of daclizumab in conjuction with low-dose cyclosporine, mycophenolate mofetil and steroids results in a low incidence of acute rejection after renal transplantation. Scand J Immunol 58 (2003) 670
14. Vincentia F., Paceb D., Birnbauma J., et al. Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation. Am J Transpl 3 (2003) 50
15. Ahsan N., Holman M.J., Jarowenko M.V., et al. Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation. Am J Transpl 2 (2002) 568
16. Vincenti F., Garrod K., Herrera R., et al. Importance of daclizumab concentrations in immunosuppression effectiveness: in vitro and in vivo analysis. Transplantation 74 (2002) 4
17. Shu-Ming J.I. Anti-CD25 minoclonal antibody in renal transplanted recipients. J Transpl 4 (2006) 84
18. Kupiec-Weglinski J.W., Hahn H.J., Kirkman R.L., et al. Cyclosporine potentiates the immunosuppressive effects of anti-interleukin 2 receptor monoclonal antibody therapy. Transplant Proc 20 suppl 2 (1988) 207